Grifols SA has published its financial results for the year ending December 31, 2023, including the sale of a 20% stake in Shanghai RAAS Blood Products for approximately USD 1,800 million, impacting its financial position significantly. This filing also outlines their compliance under SEC regulations and confirms the authenticity of the reported figures and management assessments.